Skip to search formSkip to main contentSkip to account menu

troglitazone

Known as: 5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\-2,4-thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione, 5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione 
An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity. Troglitazone activates… 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (5)

2,4-thiazolidinedioneChromansCytochrome P-450 CYP3A InducersHypoglycemic Agents

Narrower (2)

CS 045Prelay
Diabetes Mellitus, Non-Insulin-DependentDrug AllergyNCIt Antineoplastic Agent TerminologyPeroxisome Proliferator-activated Receptor alpha Agonists [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-γ activators.
Highly Cited
2007
Highly Cited
2007
Selective modulation of promoter recruitment and transcriptional activity of PPARgamma.
Highly Cited
2006
Highly Cited
2006
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin
Induction of apoptosis by the death ligand TRAIL might be a promising therapeutic approach in cancer therapy. However, since not… 
Highly Cited
2003
Highly Cited
2003
Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells.
The peroxisome proliferator-activated receptor agonist troglitazone (TRO) was used for treatment of non-insulin-dependent… 
Highly Cited
2001
Highly Cited
2001
Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.
Troglitazone is one of the thiazolidinediones, a new class of oral antidiabetic compounds that are ligands of peroxisome… 
Highly Cited
2001
Highly Cited
2001
Troglitazone, a Ligand for Peroxisome Proliferator‐activated Receptor γ Inhibits Chemically‐induced Aberrant Crypt Foci in Rats
The biological roles of peroxisome proliferator‐activated receptors (PPARs) in various diseases, including inflammation and… 
Highly Cited
1999
Highly Cited
1999
Up‐regulation of uncoupling protein 3 by thyroid hormone, peroxisome proliferator‐activated receptor ligands and 9‐cis retinoic acid in L6 myotubes
Highly Cited
1998
Highly Cited
1998
Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients
Troglitazone, an oral antidiabetic agent with antioxidant properties, has previously been shown to increase the resistance of LDL… 
Highly Cited
1996
Highly Cited
1996
Erratum to: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
SummaryThe effects of troglitazone, a novel thiazolidinedione, in non-insulin-dependent diabetic (NIDDM) patients were studied in… 
Highly Cited
1995
Highly Cited
1995
Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)